SecurityRGNX / REGENXBIO Inc. (75901B107)
IndustryBiological Products, Except Diagnostic Substances (Biotech)
Common Shares Outstanding31,655,093 shares (as of 2017-12-31)
Total Insiders24
Total Directors10
Total Officers7

Stock Insider Trading (from SEC Form 4)

REGENXBIO Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

RGNX / REGENXBIO Inc. insiders include DEERFIELD PARTNERS, L.P., and Deerfield Mgmt L.P., Vasista Vittal, KARABELAS ARGERIS N, Deerfield Mgmt III, L.P., Danos Olivier, ENGLEMAN EDGAR Simpson Curran, Fox Allan M., Flynn James E, FMR LLC / Fidelity Management & Research, Yoo Stephen, DEERFIELD MANAGEMENT CO, Deerfield International Master Fund, L.P., Ali Faraz, BESHAR LUKE M, Deerfield Private Design Fund III, L.P., Christmas Patrick J., Mills Kenneth T., Abdun-Nabi Daniel, Tasse Daniel, Samuels Camille D, HAYDEN DONALD J JR, STUMP DAVID C, .

Insider Roster

Insider Dir Off 10% Shares Owned
Vasista Vittal Chief Financial Officer
X 144,783
HAYDEN DONALD J JR Director
X 0
Christmas Patrick J. SVP, General Counsel
X 16,141
Mills Kenneth T. President and CEO, Director
X X 218,530
Simpson Curran SVP, Technical Operations
X 39,500
Yoo Stephen Chief Medical Officer
X
Danos Olivier Chief Scientific Officer
X
Abdun-Nabi Daniel Director
X
Tasse Daniel Director
X
BESHAR LUKE M Director
X
STUMP DAVID C Director
X
Fox Allan M. Director, 10% Owner
X X
KARABELAS ARGERIS N Director
X
Ali Faraz Chief Business Officer
X
Samuels Camille D Director
X
FMR LLC / Fidelity Management & Research
DEERFIELD MANAGEMENT CO 10% Owner
Flynn James E 10% Owner
Deerfield Mgmt L.P. 10% Owner
Deerfield Mgmt III, L.P. 10% Owner
Deerfield Private Design Fund III, L.P. 10% Owner
Deerfield International Master Fund, L.P. 10% Owner
DEERFIELD PARTNERS, L.P. 10% Owner
X
ENGLEMAN EDGAR Director
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-05-15 4 HAYDEN DONALD J JR S X D 50.06 -9,847 0
2018-05-15 4 HAYDEN DONALD J JR M X D 0.85 9,847 9,847
2018-05-14 4 HAYDEN DONALD J JR S X D 50.04 -5,153 0
2018-05-14 4 HAYDEN DONALD J JR M X D 0.85 5,153 5,153
2018-05-15 4 Vasista Vittal S X D 50.76 -2,455 144,783 7,349,185
2018-05-15 4 Vasista Vittal S X D 49.93 -3,945 147,238 7,351,593
2018-05-15 4 Vasista Vittal S X D 49.21 -1,100 151,183 7,439,715
2018-05-09 4 HAYDEN DONALD J JR S X D 45.00 -15,000 0
2018-05-09 4 HAYDEN DONALD J JR M X D 0.85 15,000 15,000
2018-05-10 4 Christmas Patrick J. M D 12.10 15,000 16,141
2018-05-09 4 Christmas Patrick J. S X D 44.00 -10,000 1,141 50,204
2018-05-09 4 Christmas Patrick J. S X D 42.00 -5,000 11,141 467,922
2018-05-09 4 Christmas Patrick J. M X D 12.10 15,000 16,141
2018-04-20 4 Mills Kenneth T. S X D 39.93 -900 218,530 8,725,903
2018-04-20 4 Mills Kenneth T. S X D 39.48 -9,100 219,430 8,663,096
2018-04-16 4 Vasista Vittal S X D 37.85 -2,151 152,283 5,763,912
2018-04-16 4 Vasista Vittal S X D 37.34 -2,849 154,434 5,766,566
2018-04-11 4 Christmas Patrick J. S X D 39.00 -10,000 1,141 44,499
2018-04-11 4 Christmas Patrick J. M X D 12.10 10,000 11,141
2018-04-09 4 Christmas Patrick J. S X D 34.00 -10,000 1,141 38,794
2018-04-09 4 Christmas Patrick J. M X D 12.10 10,000 11,141
2018-03-26 4 Vasista Vittal S X D 30.00 -5,000 157,283 4,718,490
2018-03-20 4 Mills Kenneth T. S X D 29.55 -10,000 228,530 6,753,062
2018-03-13 4 Simpson Curran S D 33.00 -25,000 39,500 1,303,500
2018-03-13 4 Simpson Curran M D 22.00 25,000 64,500
2018-03-06 4 Vasista Vittal M D 0.85 60,000 162,283
2018-02-28 4 Vasista Vittal S X D 30.00 -5,000 102,283 3,068,490
2018-02-20 4 Mills Kenneth T. S X D 26.56 -10,000 238,530 6,335,357
2018-01-22 4 Mills Kenneth T. S X D 27.33 -10,000 248,530 6,792,325
2018-01-16 4 Vasista Vittal S X D 30.16 -5,000 107,283 3,235,655
2018-01-11 4 Mills Kenneth T. M D 0.85 150,000 258,530
2018-01-05 4 Vasista Vittal M D 0.85 30,000 112,283
2017-12-29 4 Christmas Patrick J. A D 17.425 486 1,141
2017-06-30 4 Christmas Patrick J. A D 15.725 655 655
2017-12-22 4 Simpson Curran S X D 33.03 -30,000 39,500 1,304,685
2017-12-22 4 Simpson Curran M X D 22.00 30,000 69,500
2017-12-20 4 Mills Kenneth T. S X D 31.75 -10,000 108,530 3,445,828
2017-12-19 4 Vasista Vittal S X D 30.00 -4,994 82,283 2,468,490
2017-12-18 4 Vasista Vittal S X D 30.00 -6 87,277 2,618,310
2017-12-07 4 Simpson Curran S X D 30.04 -21,890 39,500 1,186,580
2017-12-07 4 Simpson Curran M X D 22.00 20,000 61,390
2017-12-07 4 Simpson Curran M X D 13.09 1,890 41,390
2017-12-04 4 Simpson Curran S X D 30.00 -110 39,500 1,185,000
2017-12-04 4 Simpson Curran M X D 13.09 110 39,610
2017-11-27 4 Simpson Curran S X D 29.31 -2,000 39,500 1,157,745
2017-11-27 4 Simpson Curran M X D 13.09 2,000 41,500
2017-11-20 4 Mills Kenneth T. S X D 27.71 -10,000 118,530 3,284,466
2017-11-20 4 Mills Kenneth T. M D 0.85 30,000 128,530
2017-11-15 4 Vasista Vittal S X D 25.30 -5,000 87,283 2,208,260
2017-10-20 4 Mills Kenneth T. S X D 33.03 -200 98,530 3,254,446
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

Bluebird Bio: Gene Therapy Best In Class

2018-05-16 seekingalpha
The current quarterly cash burn remains modest leaving most of the group with enough capital to operate through 3 to 5 years. (96-3)

REGENXBIO's (RGNX) CEO Ken Mills on Q1 2018 Results - Earnings Call Transcript

2018-05-12 seekingalpha
Good day, ladies and gentlemen, and welcome to the first quarter 2018 REGENXBIO earnings conference call. [Operator Instructions] (5-0)

Institutional Top Ideas Series: Ra Capital Management

2018-05-10 seekingalpha
Today's fund in the spotlight, Ra CapitalManagement, has the best performance of the funds we´ve looked at so far. (190-2)

3 Things In Biotech, May 5: Mallinckrodt Snubbed, Regenxbio Races, Portola Surprises

2018-05-06 seekingalpha
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious. (5-0)

REGENXBIO: An Underappreciated Leader In Gene Editing

2018-04-21 seekingalpha
Perhaps the biggest winner of the Novartis (NVS) buyout of AveXis (AVXS) for $8.7 billion was REGENXBIO (RGNX). REGENXBIO licenses out its adeno-associated virus (AAV) technology to other gene editing companies, including AveXis. This acquisition immediately benefited AveXis shareholders, but the true value may lie with REGENXBIO. REGENXBIO’s technology platform is the backbone of everything AveXis does and Novartis just gave a huge vote of confidence to that platform. (12-1)